Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics (NQ: SGMO )

0.8226 -0.0254 (-3.00%)
Streaming Delayed Price Updated: 2:28 PM EDT, Sep 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sangamo Therapeutics

< Previous 1 2 3 4 5 6 Next >
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Why Sangamo Therapeutics Stock Is Soaring
Sangamo Therapeutics shares are trading higher Tuesday after the company announced it has entered into a license agreement with Genentech to develop intravenously administered genomic medicines for... 
Via Benzinga
Why Is Sangamo Therapeutics (SGMO) Stock Up 52% Today?
Sangamo Therapeutics stock is heading higher on Tuesday as SGMO investors react to a new $50 million license agreement. 
Via InvestorPlace
Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases
From Sangamo Therapeutics, Inc.
Via Business Wire
Peering Into Sangamo Therapeutics's Recent Short Interest
Via Benzinga
4 Analysts Assess Sangamo Therapeutics: What You Need To Know
Via Benzinga
Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Is Sangamo Therapeutics (SGMO) Stock Up 40% Today?
Little-known firm Sangamo Therapeutics is surging today, with SGMO stock up more than 40% on promising late-stage trial results. 
Via InvestorPlace
Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings
Via Benzinga
Exposures Fossil Fuels
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study
Pfizer's Phase 3 AFFINE study of giroctocogene fitelparvovec gene therapy for hemophilia A meets key endpoints, showing a significant reduction in annualized bleeding rate. 
Via Benzinga
Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate
From Sangamo Therapeutics, Inc.
Via Business Wire
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
Via AB Newswire
Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know
Via Benzinga
SGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses Revenue for Q1 2024
SGMO stock results show that Sangamo Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Sangamo Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
From Sangamo Therapeutics, Inc.
Via Business Wire
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term... 
Via Benzinga
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
From Sangamo Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. 
Via Benzinga
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.